Highly specific and potently activating Vγ9Vδ2-T cell specific nanobodies for diagnostic and therapeutic applications

被引:25
|
作者
de Bruin, Renee C. G. [1 ]
Lougheed, Sinead M. [1 ]
van der Kruk, Liza [1 ]
Stam, Anita G. [1 ]
Hooijberg, Erik [2 ]
Roovers, Rob C. [3 ]
Henegouwen, Paul M. P. van Bergen En [3 ]
Verheul, Henk M. W. [1 ]
de Gruijl, Tanja D. [1 ]
van der Vliet, Hans J. [1 ]
机构
[1] Vrije Univ Amsterdam Med Ctr, Dept Med Oncol, Room 3A38,De Boelelaan 1117, NL-1081 HV Amsterdam, Netherlands
[2] Vrije Univ Amsterdam Med Ctr, Dept Pathol, De Boelelaan 1117, NL-1081 HV Amsterdam, Netherlands
[3] Univ Utrecht, Fac Sci, Dept Cell Biol, Padualaan 8, NL-3584 CH Utrecht, Netherlands
关键词
Nanobody; Single-domain antibody fragment; VHH; Gamma delta T cells; Flow cytometry; MACS; Immunocytochemistry; Immunotherapy; Cancer; DELTA T-CELLS; CANCER-IMMUNOTHERAPY; ANTIBODY FRAGMENTS; ANTIGEN RECEPTOR; ALBUMIN-BINDING; LIGHT-CHAINS; RECOGNITION; DOMAIN; PHOSPHOANTIGENS; MODULATION;
D O I
10.1016/j.clim.2016.06.012
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
V gamma 9V delta 2-T cells constitute the predominant subset of gamma delta-T cells in human peripheral blood and have been shown to play an important role in antimicrobial and antitumor immune responses. Several efforts have been initiated to exploit these cells for cancer immunotherapy, e.g. by using phosphoantigens, adoptive cell transfer, and by a bispecific monoclonal antibody based approach. Here, we report the generation of a novel set of V gamma 9V delta 2-T cell specific VHH (or nanobody). VHH have several advantages compared to conventional antibodies related to their small size, stability, ease of generating multispecific molecules and low immunogenicity. With high specificity and affinity, the anti-V gamma 9V delta 2-T cell receptor VHHs are shown to be useful for FACS, MACS and immunocytochemistry. In addition, some VHH were found to specifically activate V gamma 9V delta 2-T cells. Besides being of possible immunotherapeutic value, these single domain antibodies will be of great value in the further study of this important immune effector cell subset. (C) 2016 The Authors. Published by Elsevier Inc.
引用
收藏
页码:128 / 138
页数:11
相关论文
共 50 条
  • [1] A bispecific nanobody approach to leverage the potent and widely applicable tumor cytolytic capacity of Vγ9Vδ2-T cells
    de Bruin, Renee C. G.
    Veluchamy, John P.
    Lougheed, Sinead M.
    Schneiders, Famke L.
    Lopez-Lastra, Silvia
    Lameris, Roeland
    Stam, Anita G.
    Sebestyen, Zsolt
    Kuball, Juergen
    Molthoff, Carla F. M.
    Hooijberg, Erik
    Roovers, Rob C.
    Di Santo, James P.
    Henegouwen, Paul M. P. van Bergen En
    Verheul, Henk M. W.
    de Gruijl, Tanja D.
    van der Vliet, Hans J.
    ONCOIMMUNOLOGY, 2018, 7 (01):
  • [2] Specific Requirements for Vγ9Vδ2 T Cell Stimulation by a Natural Adenylated Phosphoantigen
    Vantourout, Pierre
    Mookerjee-Basu, Jayati
    Rolland, Corinne
    Pont, Frederic
    Martin, Helene
    Davrinche, Christian
    Martinez, Laurent O.
    Perret, Bertrand
    Collet, Xavier
    Perigaud, Christian
    Peyrottes, Suzanne
    Champagne, Eric
    JOURNAL OF IMMUNOLOGY, 2009, 183 (06) : 3848 - 3857
  • [3] The PPARα pathway in Vγ9Vδ2 T cell anergy
    Poupot, Mary
    Boissard, Frederic
    Betous, Delphine
    Bardouillet, Laure
    Fruchon, Severine
    L'Faqihi-Olive, Fatima
    Pont, Frederic
    Mekaouche, Mourad
    Ingoure, Sophie
    Sicard, Helene
    Dubreuilh, Guy
    Fournie, Jean-Jacques
    CELLULAR & MOLECULAR BIOLOGY LETTERS, 2014, 19 (04) : 649 - 658
  • [4] Prevention of Vγ9Vδ2 T Cell Activation by a Vγ9Vδ2 TCR Nanobody
    de Bruin, Renee C. G.
    Stam, Anita G. M.
    Vangone, Anna
    Henegouwen, Paul M. P. van Bergen en
    Verheul, Henk M. W.
    Sebestyen, Zsolt
    Kuball, Jurgen
    Bonvin, Alexandre M. J. J.
    de Gruijl, Tanja D.
    van der Vliet, Hans J.
    JOURNAL OF IMMUNOLOGY, 2017, 198 (01) : 308 - 317
  • [5] CD1d-Restricted Antigen Presentation by Vγ9Vδ2-T Cells Requires Trogocytosis
    Schneiders, Famke L.
    Prodoehl, Jan
    Ruben, Jurjen M.
    O'Toole, Tom
    Scheper, Rik J.
    Bonneville, Marc
    Scotet, Emmanuel
    Verheul, Henk M. W.
    de Gruijl, Tanja D.
    van der Vliet, Hans J.
    CANCER IMMUNOLOGY RESEARCH, 2014, 2 (08) : 732 - 740
  • [6] Synthesis of a Phosphoantigen Prodrug that Potently Activates Vγ9Vδ2 T-Lymphocytes
    Hsiao, Chia-Hung Christine
    Lin, Xiaochen
    Barney, Rocky J.
    Shippy, Rebekah R.
    Li, Jin
    Vinogradova, Olga
    Wiemer, David F.
    Wiemer, Andrew J.
    CHEMISTRY & BIOLOGY, 2014, 21 (08): : 945 - 954
  • [7] Glycolysis inhibition affects proliferation and cytotoxicity of Vγ9Vδ2 T cells expanded for adoptive cell therapy
    Aehnlich, Pia
    Santiago, Marta Velasco
    Dam, Soren Helweg
    Salo, Sara Fresnillo
    Rahbech, Anne
    Olsen, Lars Ronn
    Straten, Per thor
    Desler, Claus
    Olofsson, Gitte Holmen
    CYTOTHERAPY, 2024, 26 (09) : 1033 - 1045
  • [8] Chemotherapy and zoledronate sensitize solid tumour cells to Vγ9Vδ2 T cell cytotoxicity
    Mattarollo, Stephen R.
    Kenna, Tony
    Nieda, Mie
    Nicol, Andrew J.
    CANCER IMMUNOLOGY IMMUNOTHERAPY, 2007, 56 (08) : 1285 - 1297
  • [9] Activated iNKT cells promote Vγ9Vδ2-T cell anti-tumor effector functions through the production of TNF-α
    Schneiders, Famke L.
    de Bruin, Renee C. G.
    Santegoets, Saskia J. A. M.
    Bonneville, Marc
    Scotet, Emmanuel
    Scheper, Rik J.
    Verheul, Henk M. W.
    de Gruijl, Tanja D.
    van der Vliet, Hans J.
    CLINICAL IMMUNOLOGY, 2012, 142 (02) : 194 - 200
  • [10] The PPARα pathway in Vγ9Vδ2 T cell anergy
    Mary Poupot
    Frédéric Boissard
    Delphine Betous
    Laure Bardouillet
    Séverine Fruchon
    Fatima L’Faqihi-Olive
    Frédéric Pont
    Mourad Mekaouche
    Sophie Ingoure
    Hélène Sicard
    Guy Dubreuilh
    Jean-Jacques Fournié
    Cellular & Molecular Biology Letters, 2014, 19 : 649 - 658